Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incyte Corp
(NQ:
INCY
)
66.39
-0.04 (-0.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Incyte Corp
< Previous
1
2
3
4
5
6
Next >
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
July 31, 2023
From
Incyte
Via
Business Wire
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
July 11, 2023
From
Incyte
Via
Business Wire
Incyte to Report Second Quarter Financial Results
July 11, 2023
From
Incyte
Via
Business Wire
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
May 25, 2023
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
May 23, 2023
From
Incyte
Via
Business Wire
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
May 08, 2023
From
Incyte
Via
Business Wire
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
May 02, 2023
From
Incyte
Via
Business Wire
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
May 01, 2023
From
Incyte
Via
Business Wire
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
April 20, 2023
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
April 18, 2023
From
Incyte
Via
Business Wire
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
April 16, 2023
From
Incyte and MorphoSys U.S. Inc.
Via
Business Wire
Incyte to Report First Quarter Financial Results
April 11, 2023
From
Incyte
Via
Business Wire
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
March 27, 2023
From
Incyte
Via
Business Wire
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
March 23, 2023
From
Incyte
Via
Business Wire
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
March 22, 2023
From
Incyte
Via
Business Wire
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
March 18, 2023
From
Incyte Corporation
Via
Business Wire
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
March 18, 2023
From
Incyte Corporation
Via
Business Wire
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
March 14, 2023
From
Incyte Corporation
Via
Business Wire
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
March 06, 2023
From
Incyte
Via
Business Wire
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
March 03, 2023
From
Incyte
Via
Business Wire
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
February 24, 2023
From
Incyte Corporation
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
February 16, 2023
From
Incyte
Via
Business Wire
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
February 10, 2023
From
Incyte
Via
Business Wire
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
February 07, 2023
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
January 24, 2023
From
Incyte
Via
Business Wire
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
January 17, 2023
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
December 15, 2022
From
Incyte
Via
Business Wire
Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
December 11, 2022
From
Incyte
Via
Business Wire
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
December 10, 2022
From
Incyte
Via
Business Wire
Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
December 02, 2022
From
Incyte
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.